Q-omics provides the consensus-scored BPNT2P profile across patient tissues and cancer cell-line models. BPNT2P expression is associated with patient survival in 10 of 34 cancer types, with the highest sampling consensus in UCS. Among the 18 cancer types available for tumor–normal comparison, BPNT2P is differentially expressed in 2, with the highest sampling consensus in BRCA. Additionally, BPNT2P RNA expression shows 10,437 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight UCS, BRCA, and LSCC as cancer lineages where BPNT2P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for BPNT2P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes BPNT2P survival associations across molecular data types. BPNT2P RNA expression shows survival associations in the most cancer types (10). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible BPNT2P RNA expression–survival associations across cancer types. High BPNT2P expression shows unfavorable associations in GBM, KIRC, BLCA and SKCM, but favorable associations in UCS and MESO. The UCS Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .003). Together, the overview and detailed table identify UCS as the clearest survival context for BPNT2P RNA expression.
This table summarizes BPNT2P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 2. The strongest signals are observed in LUSC for RNA.
This table ranks reproducible tumor–normal expression differences for BPNT2P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. BPNT2P shows higher tumor expression in BRCA and LUSC. The BRCA box plot shows higher BPNT2P RNA expression in tumor versus normal tissue (log2 FC = +0.102, t-test p = .033).
This table shows molecular features associated with BPNT2P in patient tissues and cancer cell lines. In patient samples, BPNT2P shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set.
